| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | CX2; IL-17C |
| WB Predicted band size | 22 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human IL17C |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于IL17C抗体的3篇示例参考文献(内容为虚构示例，仅供参考)：
1. **文献名称**：*Targeting IL-17C in Psoriasis: A Novel Therapeutic Approach*
**作者**：Schwandner, R. et al.
**摘要**：研究探讨IL-17C在银屑病皮肤炎症中的作用，通过单克隆抗体阻断IL-17C可显著减少角质细胞炎症因子释放，改善小鼠模型症状。
2. **文献名称**：*IL-17C Neutralization Attenuates Intestinal Inflammation in Experimental Colitis*
**作者**：Johnston, A. & Chen, L.
**摘要**：利用抗IL-17C抗体治疗小鼠结肠炎模型，发现其通过抑制Th17细胞活化和肠道屏障修复，显著降低结肠组织炎症水平。
3. **文献名称**：*The Role of IL-17 Family Cytokines in Autoimmunity: Focus on IL-17C*
**作者**：Ramessamy, B. et al.
**摘要**：综述IL-17C在自身免疫疾病中的独特机制，提出靶向IL-17C的抗体相较于其他IL-17成员可能具有更低的感染风险。
4. **文献名称**：*Preclinical Development of a Humanized Anti-IL17C Antibody for Inflammatory Skin Disorders*
**作者**：Genentech Research Group
**摘要**：报道一种人源化抗IL-17C抗体的临床前研究，显示其在银屑病和特应性皮炎动物模型中有效抑制炎症通路并促进表皮愈合。
(注：以上文献为示例，非真实存在，实际研究请通过PubMed或学术数据库查询。)
IL-17C, a member of the IL-17 cytokine family, is implicated in inflammatory and autoimmune diseases. Unlike other IL-17 family members (e.g., IL-17A/F), IL-17C is primarily expressed by epithelial and barrier tissues in response to pathogens or tissue damage. It binds to a heterodimeric receptor complex (IL-17RA/RE) to activate downstream pro-inflammatory pathways, including NF-κB and MAPK signaling, leading to the production of cytokines, chemokines, and antimicrobial peptides. Dysregulated IL-17C signaling has been linked to chronic inflammatory conditions such as psoriasis, asthma, inflammatory bowel disease (IBD), and atopic dermatitis.
IL-17C-targeting antibodies are therapeutic agents designed to block IL-17C activity. By inhibiting IL-17C binding to its receptor, these antibodies aim to suppress pathological inflammation while preserving other IL-17-mediated protective immune functions. Preclinical studies in murine models demonstrated efficacy in reducing disease severity in psoriasis-like skin inflammation and colitis. Clinical trials of anti-IL-17C antibodies (e.g., MOR106) have shown mixed results, with some trials halted due to insufficient efficacy, highlighting the complexity of IL-17C's role across different diseases.
Current research focuses on identifying patient subpopulations with IL-17C-driven pathology and optimizing antibody design for enhanced specificity. Safety concerns, including potential immunosuppression risks, remain under investigation. IL-17C antibodies represent a promising but challenging avenue for targeted immunomodulation in epithelial-driven inflammatory disorders.
×
